Personal, Social, Economic Impacts on Haemophilia A Patients and Caregivers: A Mixed Method Study (WE CARE) [0.03%]
血友病A患者的个人、社会和经济影响及照护者负担：一项混合研究方法研究（WE CARE）
Mridul Makkar,M Joseph John,Diksha Sarwan et al.
Mridul Makkar et al.
Introduction: Haemophilia is a bleeding disorder with implications beyond clinical symptoms, affecting patients' and caregivers' personal, social, and economic well-being and quality of life. Limited data exist from low- ...
Severe Congenital Factor X Deficiency in an Indian Child With a Concomitant Novel ITGA2 Variant [0.03%]
一名同时伴有新型ITGA2变异的印度儿童重症先天性因子X缺乏症病例报告
Vasant Kumar,Debadrita Ray,Manu Jamwal et al.
Vasant Kumar et al.
In Vitro Spiking Comparison of Coagulation Potential Between Emicizumab and Mim8 in Whole Blood and Plasma From a Single Patient With Severe Hemophilia A Receiving FVIII Prophylaxis and Warfarin [0.03%]
在服用第八凝血因子预防治疗和华法林的严重甲型血友病单个患者全血和血浆中，Emicizumab与Mim8体外诱发凝集潜力的比较
Yuto Nakajima,Tomofumi Yoshimoto,Hiroaki Yaoi et al.
Yuto Nakajima et al.
Comparison of IPAQ-SF Self-Reported and Fitbit-Measured Physical Activity in Young People With Haemophilia [0.03%]
青年血友病患者中IPQA-SF自我报告与Fitbit检测的身体活动比较研究
Ruth Elise D Matlary,Pål André Holme,Corina S Rueegg et al.
Ruth Elise D Matlary et al.
Emerito Carlos Rodriguez-Merchan
Emerito Carlos Rodriguez-Merchan
Background: People with mild haemophilia (PMH) may require surgical treatment. Purpose: To analyse the literature related to surgery in...
Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half-Life FVIII versus Non-FVIII Therapies [0.03%]
延长半衰期F VIII与非F VIII治疗对儿科A型血友病患者凝血酶生成的影响
Jessica Garcia,Sean G Yates,Ravi Sarode et al.
Jessica Garcia et al.
Introduction: The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half-life FVIII (EHL-FVIII) and non-FVIII therapies that mimic FVIII, such as emicizumab...
Challenges and Opportunities in Post-Marketing Reporting of Factor VIII Inhibitors With Efanesoctocog Alfa [0.03%]
艾尼昔珠单抗上市后Ⅷ因子抑制物挑战与机遇
Jennifer Dumont,Linda Bystricka,Graham Neill et al.
Jennifer Dumont et al.
miR-450b-5p is a Key Molecular Mediator in the Development of Haemophilic Arthropathy [0.03%]
miR-450b-5p在血友病性关节炎发生发展中的关键作用研究
Mohankumar B Senthilkumar,Pratiksha Sarangi,Sonal Amit et al.
Mohankumar B Senthilkumar et al.
Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels [0.03%]
用于严重甲型血友病患者的ValoctocogeneRoxaparvovec治疗使FVIII水平持续保持正常上限附近
Kerstin Herbst,Behnaz Pezeshkpoor,Claudia Klein et al.
Kerstin Herbst et al.
Introduction: Valoctocogene roxaparvovec, an adeno-associated virus (AAV)-based gene therapy, enables endogenous factor VIII (FVIII) expression in patients with severe hemophilia A without the need for regular FVIII infus...
National Bleeding Disorder Foundation Clinical Practice Recommendations for Laboratory Screening of Iron Deficiency With and Without Anemia in the Inherited Bleeding Disorders Population [0.03%]
国家出血性疾病基金会的临床实践建议：在遗传性出血障碍人群中筛查伴有或不伴贫血的铁缺乏（实验室检查）
Glaivy Batsuli,Magdalena D Lewandowska,Ming Y Lim et al.
Glaivy Batsuli et al.
Introduction: The National Bleeding Disorder Foundation (NBDF) Medical and Scientific Advisory Council (MASAC) was formed in 1954 and issues recommendations and advisories pertinent to the bleeding disorders community. MA...